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Abstract
Background: In the United States, people with relapsing-remitting multiple sclerosis (RRMS) can face difficulty accessing
disease-modifying therapies (DMTs) because of insurance, pharmacy, or provider policies. These barriers have been associated
with poor adherence and negative health outcomes.
Objective: The goals of this study were to describe the overall occurrence of difficulties and delays associated with gaining
access to DMTs among people with RRMS, to assess DMT adherence during periods of reduced access, and to contextualize the
patients’ journey from receipt of a prescription for DMT to obtaining and taking their medication when faced with access barriers.
Methods: We recruited US-based adults self-reporting RRMS from a Web-based health data-sharing social network,
PatientsLikeMe. Individuals were invited to complete a Web-based survey if they reported a diagnosis of RRMS and were
prescribed a DMT for MS. Follow-up phone interviews were conducted with 10 respondents who reported experiencing an
MS-related relapse during the time they had experienced challenges accessing DMTs.
Results: Among 507 survey completers, nearly half were either currently experiencing an issue related to DMT assess or had
difficulty accessing a DMT in the past (233/507, 46.0%). The most frequently reported reasons for access difficulty were
authorization requirements by insurance companies (past issues: 78/182, 42.9%; current issues: 9/42, 21%) and high out-of-pocket
costs (past issues: 54/182, 29.7%; current issues: 13/42, 31%). About half (20/39, 51%) of participants with current access issues
and over a third (68/165, 41.2%) of those with past issues went without their medication until they could access their prescribed
DMT. Relapses were reported during periods of reduced DMT access for almost half (56/118, 47.5%) of those with past issues
and nearly half (22/45, 49%) of those with current issues. Resolving access issues involved multiple stakeholder agents often
coordinated in a patient-led effort. Among those who had resolved issues, about half (57/119, 47.9%) reported that doctors or
office staff were involved, under half (48/119, 40.3%) were involved themselves, and about a third (39/119, 32.8%) reported the
drug manufacturer was involved in resolving the issue. Follow-up interviews revealed that the financial burden associated with
obtaining a prescribed DMT led to nonadherence. Additionally, participants felt that DMT treatment delays and stress associated
with obtaining the DMT triggered relapses or worsened their MS.
Conclusions: This study expands current research by using a patient-centered, mixed-methods approach to describe barriers to
MS treatment, the process to resolve barriers, and the perceived impact of treatment barriers on outcomes. Issues related to DMT
access occur frequently, with individuals often serving as their own agents when navigating access difficulties to obtain their
medication(s). Support for resolution of DMT access is needed to prevent undue stress and nonadherence.
(J Med Internet Res 2018;20(10):e11168)   doi:10.2196/11168
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Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the
central nervous system affecting an estimated 450,000-550,000
people in the United States [1,2]. The financial burden
accompanying MS is a central component of the disease
experience, ranking second among all chronic conditions in
direct costs behind congestive heart failure [3]. In addition to
the impact of decreased productivity and unemployment [4-6],
patients often shoulder the burden of high out-of-pocket costs
for medications, tests, magnetic resonance imaging (MRI),
medical equipment, and inpatient or outpatient visits [3,7,8].
Disease-modifying therapies (DMTs) slow the disease
progression and related disability and are the prevailing
treatment for people with MS [9]. Responding to rising costs
of DMTs [10,11], insurers have adopted strategies to optimize
the utilization of specialty medications through management,
including requiring prior authorization, step therapy (where a
patient must fail a preferred medication first), or tiered
formularies that increase cost sharing for patients [12,13].
Falling into the “specialty drug” tier of most benefits plans,
DMTs are subject to higher out-of-pocket costs (ie, tiers that
require high coinsurance or copayment) than nonspecialty drugs
[14]. Due to the clinical benefits of specialty drugs like DMTs,
their use remains relatively insensitive to such cost-sharing
programs [14,15]. For people with MS, high out-of-pocket costs
for DMTs have been associated with lower adherence and
inappropriate disease management, which leaves patients at
increased risk of relapse and payers vulnerable to increased
associated resource use [16,17].
A growing body of research has explored the impact of current
insurance coverage and related barriers to DMT access on people
with MS. An estimated 25% of people with MS taking DMTs
receive these drugs at little to no cost through pharmaceutical
company financial aid programs, and such programs have been
shown to increase the adherence [18,19]. Discounted drug
programs can be essential in mitigating prohibitive financial
barriers for patients; however, regulations may prevent those
with government-based insurance coverage from using these
programs [20], so they may not be an ideal solution for all
patients.
One understudied aspect of access to MS DMTs is the patient
experience in navigating the treatment acquisition landscape.
Although prior research has focused on the number of people
receiving DMTs, how they paid for their treatment, and
insurance-related access barriers [19], it is not yet clear how
people with MS perceive and navigate the current health care
system to obtain their medication and how they perceive this
impacts their health outcomes and self-reported quality of life.
The goals of this study are to describe the overall occurrence
of difficulties and delays associated with gaining access to
DMTs among people with MS, to assess the impact of access
barriers on DMT medication adherence and MS outcomes, and
to contextualize the experience of obtaining a DMT after the
receipt of a prescription.
Methods
Study Design
This mixed-methods study included a population of people with
MS who were members of PatientsLikeMe as of February 2016.
PatientsLikeMe is a real-time, data-sharing, and research
platform of patient communities devoted to a variety of
life-changing health conditions. As of July 1, 2018,
PatientsLikeMe had >600,000 members with >2800 different
health conditions, including 59,853 members with MS, and
among those reporting their variant of MS, most (32,732/50,868,
64.35%) reported having relapsing-remitting MS (RRMS). Of
note, participants were not compensated. This study was
exempted from review by the New England Independent Review
Board on February 26, 2016 (study #16-082).
The study was designed into 2 distinct phases, consisting of a
Web-based survey and qualitative interviews following the
survey completion with a subset of survey participants who had
experienced a relapse during their access issue.
Phase 1: Web-Based Survey
A sample of people with RRMS from the PatientsLikeMe
community participated in a cross-sectional, Web-based
questionnaire fielded by PatientsLikeMe [21]. A closed design
was used, meaning only members of PatientsLikeMe who were
invited to take part and who had logged in with their password
could see the survey. An informed consent document was
displayed prior to starting the survey, and a waiver of
documentation of informed consent was obtained from the New
England Independent Review Board. The survey was
administered electronically for 4 weeks in February and March
2016.
Survey Development
The survey included demographics and a series of questions
concerning experiences with access to DMTs. We used 3
mutually exclusive branching options to segment respondents
who (1) were currently experiencing a DMT access barrier, (2)
had past (but not current) barrier accessing DMTs, and (3) never
experienced an access barrier to their DMTs. Preliminary survey
items were derived from targeted literature review and
consultation with MS experts; a PatientsLikeMe patient member
(DM) provided feedback on items, survey length, and participant
interpretability. Prior to fielding the survey, it went through a
series of reviews among investigators and was electronically
pretested for design elements, question ordering, and flow; see
Multimedia Appendix 1 for survey questions.
Survey Population
Eligible participants were aged ≥18 years, who self-reported
residence within the United States, reported a physician
diagnosis of RRMS, and had a recent (90-day) activity on the
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PatientsLikeMe website. Eligible participants were sent a private
survey invitation through the PatientsLikeMe website. Notably,
participants were screened out if they did not confirm the above
eligibility criteria or reported never being prescribed a DMT
for RRMS.
Measures
DMT access barriers included any of the following: lack of
insurance; insurance not covering the DMT; prior authorization
documentation requirement; high out-of-pocket costs;
requirement to take another DMT before the prescribed DMT
(ie, step through); inability to obtain the DMT at their desired
pharmacy or infusion center; or other difficulties.
Adherence was measured by asking participants how often they
take their medication as prescribed. Responses could be given
in 10% increments from 0% (none of the time) to 100%
(always).
Health literacy was measured using respondents’ level of
confidence filling out medical forms by themselves [22,23]. In
addition, a dichotomous variable was created to classify those
who were “quite a bit” or “extremely” confident as having high
health literacy; those who responded “somewhat,” “a little,” or
“not at all” as having low health literacy.
Stress was measured on a 10-point numeric scale. Respondents
who had experienced an access barrier were asked how stressful
their most recent DMT access issue was from 0 (not at all) to
10 (greatly). Those who had not experienced an access issue
were instead asked about their stress level in the last 7 days.
In addition to survey responses, most recent Patient-Determined
Disease Steps (PDDS) score [24-27] was obtained from
participants’ PatientsLikeMe profiles. PDDS is measured on a
9-point scale from 0 (Normal) to 8 (Bedridden).
Analyses
In this study, subgroups (current, past, or never had DMT issue)
were defined by the following 2 questions: “Which option best
describes your experience with accessing or receiving your
DMT medication for MS?” (current DMT access difficulty, a
past difficulty, or never had a difficulty) and “Have you ever
had any of the following difficulties accessing or receiving DMT
medications for MS?” (a select-all-that-apply list including items
such as covered by insurance plan and it required authorizing
documentation).
During analysis, it was discovered that some participants
reported they had never experienced a DMT access issue;
however, when queried about specific access issues, they
selected a specific DMT access barrier (eg, authorizing
documentation, high out-of-pocket costs, medications not
covered by insurance). For clarification, a 2-question follow-up
survey was fielded in June and July 2016 to 108 respondents
who fell into this category.
The first question was closed-ended: “Were any of the following
situations burdensome enough to delay or prevent you from
getting your DMT medication? (check all that apply).” Answer
options included (1) having to fill out paperwork or get other
documentation for DMT access or (2) DMT out-of-pocket costs
too high. The second question was open-ended: “Please tell us
a little bit more about this difficulty and the effect it had on you
(if any).”
Variables with closed-ended response options were analyzed
using descriptive and summary statistics. We used Wilcoxon
rank-sum tests to compare groups with nonnormally distributed
values; t tests were used to compare groups with normally
distributed values. An alpha value of ≤.05 was considered
significant. Statistical analyses were performed using SAS
software, version 9.4 (Cary, NC, USA). Open-ended questions
were coded for themes using conventional content analysis in
ATLAS.ti software (ATLAS.ti Scientific Software Development
GmbH, Berlin, Germany, version 5.0) [28,29].
Data Exclusion
A validated sample of survey respondents excluded 121
respondents from the analyzed sample who gave conflicting
responses to the survey branches. The total number of
respondents in the “never” category reduced from the full sample
of 507 respondents to 386.
Phase 2: Qualitative Interviews
Interview methods are described using the consolidated criteria
for reporting qualitative research [30]. During the second phase
of this study, 10 respondents who completed the questionnaire
were selected to participate in a single, 60-minute follow-up
interview between April and June 2016. Interviews were
conducted at the participants’ convenience via phone or
videoconference by researchers (KFS and BJK). The
interviewers had no prior relationship with interviewees.
Interviews were audiorecorded and transcribed. Participants
were not given transcripts or findings for review.
Interview Sample Population
Participants were selected for interviews based on their survey
response, reporting either a current or past issue with DMT
access, at least one MS relapse during the period of their DMT
access difficulty, and consent to a follow-up interview in the
first survey.
Interview Guide Development
The goal of the interview was to supplement information
collected in the questionnaire, among participants who had
experienced DMT access barriers and a negative health event
(eg, MS relapse) during the assess issue, using qualitative data
(see Multimedia Appendix 2 for the Interview Guide). The
following 4 research questions directed the interview guide: (1)
How did people resolve their DMT access issues? (2) What are
the clinical consequences of DMT access barriers? (3) What
are the impacts of DMT access issues on quality of life? and
(4) Who are the agents involved in helping people access their
DMT?
Analyses
Interviews were analyzed for themes by researchers using a
constant comparative method [31,32]. To represent interactions
between study participants and the agents or organizations
involved in resolving their access to DMTs, an aggregate
egocentric social network map was created based on the
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interviews [33,34]. To create the map, an iterative process was
used to draw connections between each interviewee and others
involved in DMT access resolution. Each subsequent interviewee
was compared with the previous ones until all connections
mentioned in the interviews were placed on the generalized
map, with the “ego” (study participant) in the center.
Results
Survey Results
Survey Sample
Of 5239 people invited to the survey, 947 viewed the invitation
and 584 participated in the survey, for a participation rate of
61.6%. A total of 507 participants completed the survey, for a
completion rate of 86.8% (507/584). A subset of 40 participants
(out of 108 who were invited) completed the follow-up survey,
for a participation rate of 85%). Among survey completers,
78.3% (397/507) were females, 89.6% (441/507) were white,
and participants were, on average, 49 years old (Table 1). Of
the survey completers, 66% (234/507) had high health literacy;
however, the percentage of those with high health literacy was
lowest among those currently experiencing access issues (25/45,
56%, of those with a current issue vs 138/188, 73.4%, of those
with a past issue and 127/153, 83.0%, of those who never had
issues had high health literacy). This difference was statistically
significant (χ21=14.6, P<.001). Median PDDS score was 4
(range, 1-8; interquartile range [IQR], 3.0), indicating some gait
disability. Of those in the validated sample, 60.4% (233/386)
had experienced difficulty accessing a DMT in the past
(188/386, 48.7%) or were currently experiencing an issue related
to DMTs access (45/386, 11.7%). Average time to receive the
originally prescribed DMT after experiencing an access barrier
was 8.3 (SD 16.5) weeks.
Reasons for Disease-Modifying Therapy Access
Difficulties
The most frequently reported reasons for DMT-related access
difficulties were “insurance required authorizing documentation”
(9/42, 21.4%, current issue and 78/182, 42.9%, past issue) and
“high out-of-pocket costs” (13/42, 31.0%, current issue and
54/182, 29.7%, past issue; Table 2). Other reasons included
administrative coordination problems among insurance
companies, pharmacies, and clinician’s offices.
Among the 40 follow-up respondents, 60% (24/40) clarified
that the DMT access barrier delayed or prevented them from
getting their DMT medication. The reasons for access problems
mirrored the results obtained from the full survey, with about
half of those who had experienced barriers attributing them to
“authorizing documentation” (58%, 14/24), a third to “high
out-of-pocket costs” (33%, 8/24), and several to “not covered
by insurance” (8%, 2/24). Furthermore, a slight majority of the
40 follow-up respondents (66%, 16/24) confirmed that their
access difficulty did not delay or prevent them from getting
their DMT.
Adherence to Prescribed Disease-Modifying Therapies
During Periods of Decreased Access
Respondents frequently went without any RRMS medication
until they could obtain their prescribed DMT. Nearly half
(68/165, 41.2%) of respondents who had experienced a past
access issue reported going without their medication(s) until
they could access their prescribed DMT, 4.8% (8/165) switched
to a different DMT, 1.8% (3/165) continued their old medication,
and 1.2% (2/165) received a different DMT until receiving the
originally prescribed DMT. Among respondents currently
experiencing a DMT access issue, about half (20/39, 51%)
responded they were not currently taking any medications for
their MS, 23% (13/39) continued their old medication, 13%
(5/39) took a newly prescribed DMT, and 3% (1/39) reported
they were instead taking a newly prescribed non-DMT
medication for MS (Table 3).
Self-reported adherence to DMT medication during an access
barrier (mean 8.97 [SD 2.47]) was significantly lower than
self-reported typical DMT adherence (mean 9.61 [SD 1.0]). A
paired t test showed that this difference was statistically
significant (t101=−2.48, P=.02).
Outcomes During Periods of Decreased
Disease-Modifying Therapy Access: Stress and Multiple
Sclerosis Relapse
Among respondents who experienced a DMT access barrier,
49% (22/45) of those with a current access issue reported at
least one MS relapse during the time of the barrier; 29.8%
(56/188) self-reported at least one MS relapse during a past
DMT access issue. The Wilcoxon rank-sum tests showed
significantly higher stress levels among those who experienced
at least one MS relapse during a past access issue (n=48; median,
8.5; IQR, 7.0-10.0) than among those who did not experience
relapse (n=113; median, 7.0; IQR, 5-9; Z=3.228, P=.001); this
effect did not reach significance for those with a current issue
(n=19; median, 10.0; IQR, 7.0-10.0 vs n=20; median 7.0; IQR,
4.3-8.8; Z=−1.835, P=.08).
Stakeholder Agents Involved in Disease-Modifying
Therapy Access
Among respondents who experienced past difficulties gaining
access to DMTs, 47.9% (57/119) involved doctors or office
staff to help resolve the DMT access issue and 40.3% (48/119)
said they were at least partially responsible for resolving the
issue themselves. The remaining agents involved in resolving
the issue were the drug manufacturers (39/119, 32.8%),
pharmacy or specialty pharmacy (31/119, 26.1%), insurance
companies (26/119, 21.8%), and infusion centers (6/119, 5.0%).
Few caregivers were involved in resolving the access barriers
(2/119, 1.7%).
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Table 1. Participant characteristics.
Never had issue
(n=153)
Past issue
(n=188)
Current issue
(n=45)
Validated samplea
(n=386)
Total completed
(N=507)
Characteristic
50.5 (9.7)48.9 (10.8)50.2 (9.7)49.7 (10.2)49.1 (10.4)Age (years), mean (SD)
115 (75.2)154 (81.9)39 (86.7)308 (79.8)397 (78.3)Female, n (%)
134 (91.2)161 (88.5)40 (90.9)335 (89.8)441 (89.6)White, n (%)
Ethnicity, n (%)
143 (96.6)173 (95.6)41 (93.2)357 (95.7)462 (94.7)Not Hispanic
1 (1-15, 1.0)1 (1-27, 1.0)1 (1-21, 3.0)1 (1-27, 2.0)1 (1-27, 1.0)Number of comorbidities, median (range, IQRb)
Educationc, n (%)
12 (9.4)21 (13.6)6 (16.2)39 (12.2)53 (12.7)High school or less
52 (40.6)56 (36.1)18 (48.6)126 (39.4)165 (39.6)Some college
45 (35.2)57 (36.8)5 (13.5)107 (33.4)131 (31.4)College degree
19 (14.8)21 (13.6)8 (21.6)48 (15.0)68 (16.3)Postgraduate work
High Health Literacyd, n (%)
127 (83.0)138 (73.4)25 (55.5)182 (65.5)234 (66.1)Quite a bit or extremely
Health Insurance Statuse, n (%)
68 (49.6)76 (45.5)18 (43.9)162 (47)209 (47.5)Employer based
10 (7.3)14 (8.4)2 (4.9)26 (7.5)34 (7.7)Direct
37 (27.0)56 (33.5)10 (24.4)103 (29.9)131 (29.8)Medicare
13 (9.5)11 (6.6)8 (19.5)32 (9.3)38 (8.6)Medicaid
3 (2.2)3 (1.8)1 (2.4)7 (2.0)7 (1.6)Military
5 (3.6)2 (1.2)1 (2.4)8 (2.3)9 (2.1)Veterans Affairs
0 (0)3 (1.8)1 (2.4)4 (1.2)8 (1.8)None
1 (0.7)2 (1.2)0 (0)3 (0.8)4 (0.8)Other
4 (1-8, 4.0)4 (1-8, 3.0)4 (1-8, 3.0)4 (1-8, 3.0)4 (1-8, 3.0)PDDSf score, median (range, IQR)
N/A56 (29.8)22 (48.9)N/AN/AgHad relapse during access issue (self-reported), n (%)
N/A8 (16.5)N/AN/AN/AAverage delay in weeksh,i, mean (SD)
aSubgroups (current, past, or never had a disease-modifying therapy [DMT] issue) were drawn from a validated sample based on the questions: “Which
option best describes your experience with accessing or receiving your DMT medication for MS?” “Never” includes only those who selected none of
the DMT access issues and “never” to “Which option best describes your experience with accessing or receiving your DMT medication for MS?”
bIQR: interquartile range.
cValidated sample, n=320
dValidated sample, n=278
eValidated sample, n=345
fPDDS: Patient Determined Disease Steps.
gN/A: not applicable.
hAsked only of those who eventually received the originally prescribed DMT.
iPast issue, n=64.
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Table 2. Reported reasons for the disease-modifying therapy (DMT) access issue.
Follow-upd, n (%)Current issuec, n (%)Past issueb, n (%)Source of access issuea
14 (58.3)9 (21.4)78 (42.9)Insurance required authorizing documentation
8 (33.3)13 (31.0)54 (29.7)High out-of-pocket costs
2 (8.3)8 (19.0)20 (11.0)Not covered by my insurance plan
N/Ae3 (7.1)17 (9.3)I do not have insurance
N/A2 (4.8)14 (7.7)Not at my desired pharmacy or infusion
N/A6 (14.3)9 (4.9)Required to take one additional DMT
N/A8 (19.0)37 (20.3)Otherf,g
N/A6 (14.3)12 (6.6)I don’t know
aAmong a validated sample of those with past or current difficulties, access reasons were only asked of those who received a DMT prescription from
their doctor. Question text for current issue was: “What difficulties are you having accessing or retrieving your DMT medication? Check all that apply”;
question text for past access issue was: “Thinking about your most recent MS DMT access issue, what difficulties did you have accessing or receiving
your DMT medication? Check all that apply.”
bPast issue, n=182.
cCurrent issue, n=42.
dFollow-up, n=24.
eN/A: not applicable.
fOther past reasons included administrative problems (n=9), provider changed or could not authorize (n=5), insurance or pharmacy denied drug or
changed policies (n=5), insurance status change (n=4), appointment or prescription delay by the provider (n=4), paperwork issue (n=2), and other (n=5).
gOther current reasons included insurance policy changes or coverage loss (n=2), doctor or hospital problems (n=2), administrative problems (n=1),
and switched drug (n=1).
Table 3. Medication status during past and current access issue.
Current issuec, n (%)Past issueb, n (%)Medication statusa
20 (51.3)68 (41.2)Not taking any medication or went without medication
N/Ad56 (33.9)I received my disease-modifying therapy (DMT) medication within a reasonable amount of time,
5 (12.8)8 (4.8)I was prescribed a new DMT instead
13 (33.4)3 (1.8)I continued taking my old medication
N/A2 (1.2)Received another DMT before receiving my prescribed DMT
1 (2.6)N/AI am taking a newly prescribed other non-DMT medication
N/A28 (17.0)Other
aAsked of respondents who had insurance or did not answer that difficulty obtaining DMT at a pharmacy or infusion center was their primary DMT
access reason. Question text for current access status was: “What other MS medication(s) are you taking while your DMT medication access issue is
being resolved?”; question text for past access issue was “Pick the option that best describes how your most recent MS DMT access issue was resolved.”
bPast issue, n=165.
cCurrent issue, n=39.
dN/A: not applicable.
Qualitative Interviews
Interview Sample
Qualitative interviews were conducted among 10 survey
respondents who experienced at least one MS relapse during a
past or current period of decreased access to DMTs. Participants
were predominantly females (9/10, 90%) with the mean age of
54 (range, 42-64) years; of them, 5 reported being on Medicaid
or Medicare, 3 on employer-sponsored insurance, 1 did not
specify insurance type, and 1 had no insurance. The median
duration of MS was 9.5 (range, 2-15) years.
Themes From Qualitative Interviews
We identified several themes in the interviews; detailed
examples are shown in Table 4.
Theme 1: Financial Burden Begins Prior to the
Disease-Modifying Therapy Access Barrier and Can Impact
Adherence to the Therapy
Many participants reported that prior to being prescribed a DMT,
they had been in financial distress due to MS diagnostic costs
and/or loss of income due to inability to work because of their
symptoms (Table 4). For example, one participant said she had
spent “all our savings” (Female, age 58 years) on medical costs
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related to her MS diagnosis, such as MRI tests. Another filed
for bankruptcy because of bills stemming from his initial MS
diagnosis. Most interviewees had stopped or reduced paid work
because of MS symptoms, and over half (6/10, 60%) sought or
received disability pay or subsisted on a fixed monthly income
lower than the amount of their monthly copayment for their
DMT medication. Most interviewees (8/10, 80%) went without
DMT medication during their access barrier; the remaining 2
took a DMT they had been prescribed in the past until the access
barrier was resolved.
Theme 2: Disease-Modifying Therapy Access Barriers are
Associated With Stress and Relapses
Many participants felt delays in DMT treatment, and the stress
associated with the process of obtaining the DMT triggered
relapses or worsened their MS. As one participant who
experienced a combination of billing errors and finding her
DMT out of stock at her infusion center asked, “Why do I have
to deal with this crap? You know how they say that stress makes
it worse?” (Female, age 56 years). Several participants
experienced worsening fatigue and cognitive problems related
to MS and the lack of DMT, making efforts to resolve their
access issue more difficult.
Theme 3: Disease-Modifying Therapy Access Issues Affect
Quality of Life
Access difficulties impacted multiple facets of participants’
lives; emotional and interpersonal impacts were commonly
mentioned. Emotional impacts included situational problems
like “frayed nerves” (female, age 58 years) and exacerbation of
pre-existing mental health comorbidities, such as depression.
In addition to the time and effort spent on trying to access a
DMT, several participants reported that the uncertainty of having
unstable health because of going without a DMT made it
difficult to schedule social events in advance.
Theme 4: Personal Resources Enable Access to Overcome
Disease-Modifying Therapy Access Barriers
Several participants who succeeded in obtaining their DMT
reported that they leveraged knowledge and skills from working
in medical billing and other health care areas to expedite the
process. This high level of health care literacy obtained through
work experience facilitated their ability to document the issue
and reach the appropriate agents who could help resolve the
problem quickly.
Table 4. Themes arising from participant interviews.
Example quotesTheme
I had to declare bankruptcy because of my first doctor’s bill. We accumulated US $15,000 in debt through the
MRIs because they only cover half of one MRI per year and I had 6 that first year…I went from making US $6500
a month to US $1400 a month [on disability] with two kids and a vehicle. I got a little part time job that’s 12 hours
a week, US $10 an hour. That pays for my drugs. [Male, age 42 years]
Patients are not getting help. We cannot afford insurance. My discretionary income is US $10, that’s why I needed
a physician who accepted cash. With co-pay, deductible and premium I could not afford that. [Female, age 45
years]
I couldn’t afford the co pay and just quit taking the DMM [disease modifying medication]. I also quit taking other
medications I could not afford to purchase. [Female, age 64 years]
Financial burden begins prior
access issue and impacts the dis-
ease-modifying therapy (DMT)
adherence
I’ve had a series of bad attacks when the prescription lapsed and when the insurance lapsed. I have some severe
damage where it comes to process from the printed page and to spit it back out again. That ability is gone unless
it’s in context…I had lesions confirmed. The area with the vocabulary. I’m also a bit slow on the processing. There
are things I don’t do so well. It takes me that little extra moment, so there’s this pause in my conversation…Those
are the two areas of the brain affected. [Female, age 58 years]
You spend 45 min fighting on the phone it’s like working 8 hours. I have to take 2-3 hours of the day for a nap to
get my energy back…I’ve done nothing but fight with [my insurance company]. [Female, age 51 years]
I had a relapse while waiting to get on [DMT]. My left arm is numb and tingling constantly. [Female, age 54 years]
DMT access problems and relat-
ed stress leads to multiple sclero-
sis relapses
When I didn’t have the medication, I have depression, and that’s not a surprise when you have MS, and it affected
me really bad, especially without the [DMT] and I can’t afford it. I kept thinking I don’t know what’s happening
inside of me and are things happening to me that I won’t be able to come back from? Not having the medication
really affected me emotionally as well.” [Female, age 59 years, on Medicare with too high co-pay]
My husband has to work 10 hour days and he’s stressed because of me. I worry about him. If I couldn’t get coverage
on HC.gov, I could have gotten on my husband’s plan but that would have been more money, more money out of
his paycheck. I went for the lesser of two evils but it’s still US $352 per month. There’s gotta be an in-between. I
look for miracles. Someone that doesn’t qualify for disability there has to be some safety net. [Female, age 51 years]
DMT access issues affect the
quality of life
I had a 2-month delay to get the authorization. The prescription took over 30 days. First, they sent it to a retail
pharmacy and it was rejected. Then it was sent to the wrong specialty pharmacy, and they denied it. Finally, after
a month, I got the prescription. I used to do billing for Medicare, so I was familiar with pharmacy denials. Someone
else would be lost, they would have had to do without their medicine. The fact that I got the prior authorization, I
knew I didn’t have to pay full-price. I knew it should be covered under my plan. [Female, age 64 years]
Personal resources enable access
to overcome DMT barrier
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Egocentric Social Network of Disease-Modifying
Therapy Access
Participants contacted numerous stakeholders during the process
of obtaining a DMT. The complexity and intensity of work
involved in resolving the problem placed a high burden on them.
As one participant described, “I do all of the legwork” (Female,
age 58 years). All interviewees contacted their insurance
company, physicians, and specialty pharmacy while trying to
obtain their DMT. Additional agents contacted included
advocacy groups, pharmaceutical companies, government
agencies, and hospitals. Figure 1 depicts a conceptual network
visualization of these agents as a social network diagram.
Insurance-related access problems were attributed to changes
in plans (eg, from an employer-sponsored plan to Medicare),
formulary changes by insurance companies’ pharmacy benefit
manager, or copayment payment policies. For example, a change
to the pharmacy benefit manager contracted with one woman’s
insurance company left her with different coverages, new step
therapy requirements, and without access to her DMT for months
at a time. In addition, insurance changes led to uncertainty about
future access; for example, one participant could not find
information about whether the Medicaid plan he would enter
later in the year would cover his DMT. Finally, some
participants could not afford to meet insurance requirements to
pay the full price of DMT upfront and wait to be reimbursed
later for the portion covered by the insurer.
Providers facilitated the documentation of proof of the medical
need for advocacy groups or pharmaceutical company programs
offering copayment assistance. For some, physician
documentation was easily accomplished, while for others, it
was a frustrating impediment that required additional calls or
visits, and in some cases, delayed treatment access.
Barriers at pharmacies centered around finding a specialty
pharmacy to work with their insurance and/or copayment
assistance program. Resolving these issues could involve weeks
of phone calls and research into plan coverages at specific
pharmacies. Several participants reported that insurance
companies were unable to provide accurate information about
alternative pharmacies that might cover their DMT, forcing
them to independently seek this information on the internet or
elsewhere.
Nearly all interview participants had sought financial assistance
from an advocacy group or a pharmaceutical company; this
process was marked by complexity and logistical challenges
requiring substantial investment of time and effort to prove need
and coordinate stakeholders. Participants reported a range of
experiences with patient advocacy groups, from helpful to
challenging. Some reported no problems with obtaining
copayment assistance from advocacy groups but experienced
problems elsewhere in the access process. Most described the
advocacy group funding assistance as a “grant” distributed for
a certain total amount of money, after which point they would
need to reapply. However, these organizations sometimes lacked
sufficient funds to (re-)distribute. Others described spending
dozens of hours on calls and paperwork to prove eligibility,
with one woman reporting her income was deemed US $100
too high for assistance, despite living in an expensive area with
a relatively modest income.
Pharmaceutical companies provided participants with copayment
assistance or direct access to a DMT. Some participants had
difficulty navigating the administrative paperwork necessary
to access their copayment assistance programs, which could
require original signatures that some found difficult to obtain.
Figure 1. The aggregate egocentric social network of disease-modifying therapy access resolution based on 10 people with multiple sclerosis who
experienced a relapse during their access issue.
J Med Internet Res 2018 | vol. 20 | iss. 10 | e11168 | p.8http://www.jmir.org/2018/10/e11168/
(page number not for citation purposes)
Simacek et alJOURNAL OF MEDICAL INTERNET RESEARCH
XSL•FO
RenderX
Others reported that pharmaceutical companies’ copayment
assistance programs were helpful facilitators, coordinating
copayment assistance among patients, providers, and pharmacies
or in one instance directly sending medication to a patient when
the insurance company and the pharmacy failed to work with
the pharmaceutical company’s copayment assistance program.
Two interviewees contacted government agencies to enforce
the insurance coverage of DMTs that were not being followed;
this required additional effort and knowledge to access services
to enforce coverage of DMTs.
Finally, participants reported that their families provided
emotional and financial support, working to provide insurance
and encouraging them to keep trying until they obtained their
DMT. However, several reported they felt they were a burden
to their spouse or other family members.
Discussion
Principal Findings
In the United States, people with MS can face difficulty
accessing DMTs because of insurance, pharmacy, or provider
policies. This study demonstrated that issues related to DMT
access occur frequently, commonly because of the need for
authorizing the documentation, high out-of-pocket costs, and
agency or provider coordination problems. Furthermore,
participants reported that the effort to overcome barriers could
be exceptionally time consuming, complex, and stressful for
people with RRMS. This effort required contacting multiple
stakeholders in their care administration, including providers,
insurers, patient advocacy groups, and others. Furthermore,
owing to the lack of DMT, people may navigate this complex
process while experiencing disease progression and worsening
symptoms. Some participants reported experiencing negative
health outcomes during this lack of access, including relapse.
This work represents one of the few studies to both detail the
frequency of DMT access issues as well as highlights the patient
perspective throughout the DMT acquisition process and the
impact this may have on their health outcomes. Furthermore,
this study uses a novel approach, blending quantitative and
qualitative methods to illuminate the patient experience with
DMT access barriers from their own perspective. This approach
offers depth and real-world insight that cannot be observed from
administrative sources such as claims databases.
Comparison With Prior Work
These findings confirm previous research showing that
insurance-related access barriers can be associated with adverse
outcomes, such as suboptimal adherence, which is associated
with higher medical costs [35-41]. Similar to other studies with
people with MS, participants in this study reported that before
the DMT issue, many had to reduce or stop working because
of functional cognitive decline related to MS [4-6,42,43]. Noting
the burden of cost, paperwork, and benefit changes on people
with MS trying to obtain DMT, medication advocacy
organizations and provider groups have called for system-wide
transparency, lower drug prices for DMTs, and policy reforms
to assist people with MS with the cost burden of their care
[8,44,45].
While the Affordable Care Act of 2010 was implemented to
benefit patients by improving the overall health insurance access
[46], many patients still lack access to DMTs because of their
high cost and specialty status [14]. Cost-sharing efforts on the
part of payers have forced many patients to seek financial
assistance to defray the costs of DMTs [19,47]. This study
showed that even when these programs are available, the
logistics of taking part are complex, burdensome, and sometimes
unsuccessful, leading to elevated stress levels and, potentially,
relapse.
Limitations
There are several limitations of our study which deserve
mention. The generalizability of PatientsLikeMe patient
population may not reflect the general population of people with
MS as users of health-based internet sites are more likely to be
female, younger, and more educated than those sampled from
a clinic [48]. Results from interviews are not representative of
all people with MS on PatientsLikeMe, nor those who completed
the survey, as they were selected to include only those who
experienced difficulty obtaining a DMT. Patient-reported
explanations for DMT access difficulties are subject to errors
in recall and errors in the reconstruction of events, especially
among participants who reported MS relapse during the access
issue. Finally, as the interview sample size was likely not
sufficient to achieve concept saturation, resultant themes should
be interpreted with caution.
Conclusions
This study stresses the need for future research to incorporate
the patient perspective to better understand barriers to MS
treatment access. The evaluation of the long-term impact of
DMT access barriers on patient and disease outcomes are
needed. Formulary decision makers must consider the patient
experience when making DMT coverage decisions. Clinicians
should be aware of how patients experience DMT access
difficulties and help deliver solutions to them when feasible.
The MS patient experience with DMT access will continue to
evolve with ongoing policy and payer landscape changes. Hence,
frequent feedback from people with MS and stakeholders will
be of paramount importance to ensure access to DMTs and to
measure the associated impact on outcomes.
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